NCT05005312View on ClinicalTrials.gov

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

PHASE1CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

December 7, 2021

Study Completion Date

December 7, 2021

Conditions

Hepatic Impairment

Interventions

DRUG

PF-07321332

Tablet

DRUG

Ritonavir

PK Boosting agent

Trial Locations (2)

55114

Prism Research LLC dba Nucleus Network, Saint Paul

92780

Orange County Research Center, Tustin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT05005312 - Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332 | Biotech Hunter | Biotech Hunter